Search

Amivantamab

[A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022. … [L41469] On December 17, 2025, the U.S.

Influenza A virus A/South Australia/34/2019 IVR-197 (H3N2) antigen (formaldehyde inactivated)

Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

Chlordiazepoxide

An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.

Metocurine iodide

Metocurine Iodide is no longer available on the US market. … It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine

Eugenol

Eugenol is a naturally occurring phenolic molecule found in several plants such as cinnamon, clove, and bay leaves. … It has been used as a topical antiseptic as a counter-irritant and in dental preparations with zinc oxide for root canal sealing and pain control.

Chlorobutanol

Chlorobutanol, or chlorbutol, is an alcohol-based preservative with no surfactant activity [A32746]. … Similar in nature to chloral hydrate, it is formed by the simple nucleophilic addition of chloroform and acetone.

Tecovirimat

[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. … [L3626, L3614] Tecovirimat was later approved by Health Canada in December 2021,[L39397] followed by the approval from the European Commission in January 2022.

Lumacaftor

results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. … , and improvements in CF symptoms.

Isosulfan blue

Mitapivat

[A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953] … Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells.